Loading company…
Stayble Therapeutics develops injection-based treatments for chronic pain from spinal disc conditions.
Stayble Therapeutics is developing STA363, an injection-based treatment for degenerative disc disease and herniated discs. Founded in 2015 and based in Gothenburg, Sweden, the company raised SEK 32 million from Chalmers Ventures in July 2023 to support a Phase 2b study and development of its portfolio.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in